lgoTx, a French Biotech developing ATX01 for the treatment of Chemotherapy-Induced Peripheral Neuropathy, announced on February 11th 2019 the appointment of Axel Le Cesne to its Scientific Advisory Board, followed by the appointment of Alain Eschalier on May 19th 2019.

Axel Le Cesne

Axel Le Cesne is Associate Professor of Medicine. Head of Medical Oncology Hospital Unit at Gustave Roussy, France. He headed the Bone/Soft Tissue Sarcoma Unit from 1995 to 2016. Axel is a member of ASCO, ESMO, EORTC Soft Tissue and Bone Sarcoma Group (STBSG). He served as Co-chair & Secretary of the French Sarcoma Group 2001-2005 and has been a member of the Board of Directors of the Connective Tissue Oncology Society since 2010. Axel is a member of French Academy of Medicine.

Alain Eschalier

Alain Eschalier is a pharmacist, a Medical Doctor and a Pharmacologist. He is Professor of Medical Pharmacology and former President of the Université d’Auvergne. Alain created and led several research units within INSERM and chairs the Analgesia Institute.

AlgoTx’ Scientific Advisory Board is chaired by Céline Greco (MD Phd), Hosp. Practitioner, Pain and Palliative Medicine Care Unit at the Hôpital Necker Enfants Malades in Paris. Céline heads up the Reference Center for Mastocytosis and genetic disease with cutaneous expression. She is a laureate of the INSERM-Bettencourt school, and a Member of the Board  of the Council for Children Protection.

Axel Le Cesne and Alain Eschalier join the following Members of the Scientific Advisory Board :

Ronald Levy is Professor of Médecine, Stanford University Dpt of Oncology. He was awarded the Faisal International Prize, the Damashek Prize, the American Cancer Society’s Medal of Honor, the Leukemia and Lymphoma Society’s de Villiers Intl Achievement Award, the C. Chester Stock Award Memorial Sloan-Kettering Cancer Center, and the Karnofsky Award from the American Society of Clinical Oncology.

Jean-François Bergmann is Professor of Therapeutics at Paris VII University. He headed up the Internal Medicine and Infectious Diseases Dpt at Hôpital Lariboisière, Paris. He is the President of the Medicines Committee of the Assistance Publique – Hôpitaux de Paris (AP-HP). He served as expert with the Drug Approval Committee and the Transparency Committee of the French National Medicines Agency (ANSM), and expert with the European Medicines Agency (EMA).

Ivan Krakowski is medical oncology and pain specialist. He heads up the Oncology Supportive Care at Institut Bergonié, and is the President of AFSOS (French speaking society of supportive care in oncology). Ivan is a Board Member of the National Cancer Committee and serves on the Council of EU Cancerology Training School. He is the Co-editor of « Oncologie » & « Douleur& Analgésie”.

Philippe Arnaud, PharmD, is a Hospital Practitioner and Dpt Head at Bichat – Claude Bernard Hosp. He is a Professor at Paris Descartes Pharmacy & Biological Sciences University, and Erasmus teacher in Italy, Portugal and Canda. Philippe is a Member French National Medicines Agency (ANSM).

AlgoTx is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.